Pfizer's stock is moving up by 2.25% today due to positive developments in its drug pipeline, including promising Phase 2 data for its breast cancer and atopic dermatitis treatments, which showed significant improvements in patient outcomes. Additionally, the company signed a non-exclusive licensing deal to use Novavax's Matrix-M adjuvant, which could enhance its vaccine and therapeutic offerings.
